Literature DB >> 16670048

Poor outcomes in patients with primary malignant mediastinal germ-cell tumors.

Hui-Hua Hsiao1, Yi-Chang Liu, Hui-Jen Tsai, Kun-Bow Tsai, Yu-Jen Cheng, Shah-Hwa Chou, Inn-Went Chong, Won-Chi Yang, Ta-Chi Liu, Sheng-Fung Lin.   

Abstract

Primary mediastinal germ-cell tumors (GCTs) without gonadal involvement are rare and can be divided into benign mature teratoma and malignant seminoma or nonseminoma. We describe our experience of malignant mediastinal GCTs and compare the presentations and outcome with those of benign teratomas. Four malignant GCTs (1 seminoma, 1 choriocarcinoma, and 2 yolk-sac tumors) have been treated in our hospital. All patients were men with obvious symptoms before diagnosis. The patient with seminoma was treated with surgery and radiation, while those with nonseminoma tumors were treated with chemotherapy and/or surgery. Two patients died, one with extended pulmonary metastasis and the other with relapsed disease and high levels of tumor markers. Compared with the nine cases of benign teratomas, the four malignant GCTs showed overwhelming male dominance, advanced symptoms at presentation, and poor outcome. These cases highlight the important role of disease staging and tumor-marker levels in malignant GCTs, and suggest that new treatment strategies for malignant GCTs await further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16670048     DOI: 10.1016/S1607-551X(09)70208-6

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  1 in total

1.  Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution.

Authors:  Jianyang Wang; Nan Bi; Xiaozhen Wang; Zhouguang Hui; Jun Liang; Jima Lv; Zongmei Zhou; Qin Fu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Luhua Wang
Journal:  Thorac Cancer       Date:  2015-07-02       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.